Consensus recommendations on the management of depressive disorders in pregnancy

The Italian Societies of Toxicology, Neuropsychopharmacology, Psychiatry, Obstetrics and Gynecology, Drug Addiction, and Addiction Pathology have published joint consensus recommendations regarding the management of depressive disorders in pregnancy. These recommendations focussed on five key areas including: (i) the importance of management of anxiety and depressive disorders in pregnancy; (ii) the overall risk of malformation with antidepressant and anxiolytic drugs; (iii) […]

» Read more

Congenital malformation risks following integrase inhibitor use in pregnancy

Utilising data from the Colorado-based Children’s Hospital Immunodeficiency Program (CHIP), a team of researchers have published a retrospective comparative cohort study of pregnancy and fetal outcomes following first trimester integrase inhibitor use (dolutegravir, elvitegravir or raltegravir). The study describes increased risks of congenital anomalies among the first trimester integrase inhibitor exposed in comparison with those born to women with HIV […]

» Read more
1 2 3 4 5 23